DeepMed Research

Fresenius Kabi

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Subsidiary

Established: 1999-01-01

Employees: -

Market Cap: -

Website: http://www.fresenius-kabi.com

Clinical Trials

Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy

Not Applicable

Terminated

Conditions: Aneurysmal Subarachnoid Hemorrhage

Interventions: Other: Fresubin HP Energy Fibre (1.5 kcal)
Other: Diben 1.5 kcal HP

First Posted Date: 2015-07-21

Last Posted Date: 2022-03-31

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 28

Registration Number: NCT02503527

Locations: 🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria

Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery

Phase 3

Completed

Conditions: General Anesthesia
Elective Surgery

Interventions: Drug: Diprivan
Drug: Propofol

First Posted Date: 2013-05-20

Last Posted Date: 2014-02-21

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 71

Registration Number: NCT01856998

Locations: 🇫🇷
CHU de Bordeaux, Groupe Hospitalier Pellegrin, Bordeaux, France

Fluid Resuscitation in Patients Suffering From Burns Injury

Phase 4

Terminated

Conditions: Burns

Interventions: Drug: Volulyte
Drug: Human Serum Albumin

First Posted Date: 2012-09-21

Last Posted Date: 2014-06-26

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 11

Registration Number: NCT01689506

Locations: 🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Birmingham, United Kingdom

VolulyteTM in Cardiac Surgery

Phase 4

Completed

Conditions: Heart; Dysfunction Postoperative, Cardiac Surgery

Interventions: Drug: 6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
Drug: Human serum albumin

First Posted Date: 2012-03-14

Last Posted Date: 2014-06-26

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 133

Registration Number: NCT01553617

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦
London Health Sciences Centre, London, Ontario, Canada

and more 2 locations

Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients

Not Applicable

Completed

Conditions: Diabetes

Interventions: Dietary Supplement: Oral nutritional supplement, food for special medical purposes

First Posted Date: 2010-11-16

Last Posted Date: 2012-07-02

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 40

Registration Number: NCT01241695

Locations: 🇩🇪
Medical Practice, Stockach, Baden-Württemberg, Germany

The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients

Not Applicable

Completed

Conditions: Enteral Nutrition

Interventions: Dietary Supplement: Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)
Dietary Supplement: Fresubin(R)

First Posted Date: 2009-12-03

Last Posted Date: 2010-08-20

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 111

Registration Number: NCT01025167

Locations: 🇩🇪
Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Dresden, Dresden, Germany
🇩🇪
Department of Radiotherapy, University hospital, Erlangen, Germany
🇩🇪
Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Frankfurt, Frankfurt, Germany

and more 7 locations

Voluven® in Paediatric Patients

Phase 4

Completed

Conditions: Cardiac Surgery
Cardiopulmonary Bypass

Interventions: Drug: Human serum albumin (HSA 50g/L)
Drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)

First Posted Date: 2009-03-12

Last Posted Date: 2011-11-02

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 61

Registration Number: NCT00860405

Locations: 🇦🇹
AKh Allgemeines Krankenhaus der Stadt Linz GmbH, Linz, Austria
🇧🇪
HUDERF - Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium

Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients

Not Applicable

Terminated

Conditions: Cachexia
Cancer

Interventions: Dietary Supplement: oral nutritional supplement, food for special medical purposes

First Posted Date: 2009-02-26

Last Posted Date: 2011-06-02

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 17

Registration Number: NCT00851448

Locations: 🇵🇱
Pulmonology Dept. of Miedzylesie Hospital, Warsaw, Poland
🇮🇹
Dipartimento di Medicina Clinica, La Sapienza Università, Rome, Rome, Italy
🇵🇱
Indywidualna Specjalistyczna Praktyka lekarska, Ruda Slaska, Poland

Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients

Not Applicable

Completed

Conditions: Cachexia
Chronic Obstructive Pulmonary Disease
Chronic Heart Failure

Interventions: Dietary Supplement: oral nutrition supplement, food for special medical purposes

First Posted Date: 2009-02-26

Last Posted Date: 2017-01-31

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 60

Registration Number: NCT00852020

Locations: 🇩🇪
Praxis für Pneumologie, Schwedt/Oder, Schwedt/Oder, Germany
🇵🇱
Regionalne Centrum Leczenia Chorób Płuc i Alergii, NZOZ ALLMED, Piekary Śląskie, Poland
🇵🇱
Specjalista Chorób Wewnętrznych Kardiolog, Ruda Śląska, Poland

and more 1 locations

Effectiveness and Tolerability of an Oral Nutritional Supplement (PreOP Booster) Given Before Surgery

Not Applicable

Completed

Conditions: Rectal Tumors

Interventions: Dietary Supplement: PreOP Booster (food for special medical purposes)

First Posted Date: 2008-08-08

Last Posted Date: 2010-05-19

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 20

Registration Number: NCT00730808

Locations: 🇳🇱
Medical Center Alkmaar, Alkmaar, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy